Alan G. Ramsay

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 68 publications

Orbital Extranodal Marginal-Zone Lymphoma and Crystal-Storing Histiocytosis Related to a Longstanding Silicone Scleral Buckle.

Orbital Extranodal Marginal-Zone Lymphoma and Crystal-Storing Histiocytosis Related to a Longstanding Silicone Scleral Buckle.

Journal: Ophthalmic plastic and reconstructive surgery

Published: September 02, 2026

EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

EuroNet-PHL-LP1: Complete resection or low-dose chemo for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Blood advances

Published: January 16, 2026

EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Blood advances

Published: January 16, 2026

Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis.

Systemic and Local Adiposity in the Bone Marrow Microenvironment Associated With Improved Prognosis in Hodgkin Lymphoma: Imaging and Molecular Analysis.

Journal: International journal of cancer

Published: September 11, 2025

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.

Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma.

Journal: Nature communications

Published: April 18, 2025

Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade.

Dissecting CD47 expression in lymphoid neoplasms to inform precision immunotherapy with anti-CD47 phagocytic checkpoint blockade.

Journal: Haematologica

Published: March 19, 2025

Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosis.

Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosis.

Journal: Leukemia

Published: March 10, 2025

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.

Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: January 02, 2025

Post COVID glaucoma service redesign utilising electronic patient triage and community optometry clinics (Fife, Scotland 2020-2022).

Post COVID glaucoma service redesign utilising electronic patient triage and community optometry clinics (Fife, Scotland 2020-2022).

Journal: BMC ophthalmology

Published: November 05, 2024

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T-Cell Neoplasms.

Journal: Hematological oncology

Published: September 22, 2024

The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.

The phenogenomic landscapes of pleural mesothelioma tumor microenvironment predict clinical outcomes.

Journal: Journal of translational medicine

Published: August 20, 2024

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.

Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial.

Journal: BMC cancer

Published: February 14, 2024

Showing 1-12 of 68

Last Updated: 09/26/2026